Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Total Valuation
Heron Therapeutics has a market cap or net worth of $166.23M. The enterprise value is $251.25M.
Market Cap$166.23M
Enterprise Value$251.25M
Share Statistics
Heron Therapeutics has 188,537,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding188,537,140
Owned by Insiders21.89%
Owned by Institutions32.01%
Financial Efficiency
Heron Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -1.59%.
Return on Equity (ROE)-1.41
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-1.59%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee1.27M
Profits Per Employee-165.53K
Employee Count122
Asset Turnover0.61
Inventory Turnover0.45
Valuation Ratios
The current PE Ratio of Heron Therapeutics is ―. Heron Therapeutics’s PEG ratio is -0.31.
PE Ratio―
PS Ratio1.40
PB Ratio15.12
Price to Fair Value15.12
Price to FCF-7.77
Price to Operating Cash Flow-5.33
PEG Ratio-0.31
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 154.90M and earned -20.20M in profits. Earnings per share was -0.12.
Revenue154.90M
Gross Profit113.56M
Operating Income-2.54M
Pretax Income-20.20M
Net Income-20.20M
EBITDA-17.88M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was -27.59M and capital expenditures -317.00K, giving a free cash flow of -27.91M billion.
Operating Cash Flow-27.59M
Free Cash Flow-27.91M
Free Cash Flow per Share-0.15
Dividends & Yields
Heron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change-63.14%
50-Day Moving Average1.25
200-Day Moving Average1.44
Relative Strength Index (RSI)26.56
Average Volume (3m)1.70M
Important Dates
Heron Therapeutics upcoming earnings date is May 11, 2026, Before Open (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Heron Therapeutics as a current ratio of 2.48, with Debt / Equity ratio of 981.22%
Current Ratio2.48
Quick Ratio1.51
Debt to Market Cap0.65
Net Debt to EBITDA-6.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Heron Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Heron Therapeutics EV to EBITDA ratio is -18.38, with an EV/FCF ratio of -11.78.
EV to Sales2.12
EV to EBITDA-18.38
EV to Free Cash Flow-11.78
EV to Operating Cash Flow-11.91
Balance Sheet
Heron Therapeutics has $46.63M in cash and marketable securities with $140.64M in debt, giving a net cash position of -$94.01M billion.
Cash & Marketable Securities$46.63M
Total Debt$140.64M
Net Cash-$94.01M
Net Cash Per Share-$0.50
Tangible Book Value Per Share$0.09
Margins
Gross margin is 73.31%, with operating margin of -1.64%, and net profit margin of -13.04%.
Gross Margin73.31%
Operating Margin-1.64%
Pretax Margin-13.04%
Net Profit Margin-13.04%
EBITDA Margin-11.54%
EBIT Margin-13.04%
Analyst Forecast
The average price target for Heron Therapeutics is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.50
Price Target Upside411.36% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast12.60%
EPS Growth Forecast58.23%